Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 3 of 87 · 4164 articles
These patient-derived human tissue models aim to let drug developers test whether a candidate affects disease-relevant biology in human intestinal tissue before moving to clinical trials, which could help reduce failures...
This mid‑stage trial reports strong week‑44 clinical remission and endoscopic response rates for duvakitug, an investigational anti‑TL1A therapy, in both UC and Crohn’s disease — a development that could expand future...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Personal stories like this show how surgery, nutrition, and tailored exercise can help someone with Crohn’s rebuild strength, body weight, and confidence. They can offer practical ideas and emotional encouragement to...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Tests and monitoring. The original article is from Middle East journal of digestive diseases.
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease, Ustekinumab, and IL-12/23 inhibitor. The original article is from Gastro hep advances.
Long-term risk of needing another intestinal surgery is a major concern for people with Crohn’s disease. This study suggests laparoscopic resection may be linked to lower long-term reoperation risk compared with open...
Early intestinal resection is uncommon but important in pediatric Crohn’s disease. Identifying features linked to surgery soon after diagnosis can help families and clinicians monitor higher-risk children and plan care.
Stronger, more sustainable IBD research units can increase patient access to clinical studies, speed up therapeutic and biomarker advances, and make care more research-ready. Patients and clinicians in centers with...
Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Crohn's & colitis 360.
This review connects enteric sensory neuron dysfunction to symptoms common in IBS and IBD (pain, diarrhea, constipation, dysmotility). Understanding IPAN plasticity could point to new treatment targets that act locally...
Self-management is central to long-term IBD control. The study shows many patients have limited disease knowledge and less favorable attitudes, which could affect adherence, lifestyle choices, and follow-up.
Children with Crohn’s disease may have vitamin D deficiency and a theoretical link between vitamin D levels and relapse risk; this trial tested whether adding high‑dose vitamin D3 at diagnosis could lower relapses and...
Distinguishing inflammation from irreversible fibrosis is a common clinical challenge in Crohn’s disease because it affects treatment choices (medical therapy versus surgery). Validated MRI biomarkers could improve...
Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
The study suggests Crohn’s disease is associated with coordinated brain structure and function differences that relate to disease activity and quality of life, pointing to brain–gut links that could inform future...
Staying on an immunomodulator with anti-TNF therapy was linked to greater long-term persistence of the biologic drug, which matters because loss of response to anti-TNF agents is a common problem in Crohn’s disease....
Findings suggest a dietary flavonoid (daidzein) may reduce colitis in mice via microbial activation and host signaling pathways, pointing toward microbiome-informed nutritional approaches for IBD.
Identifying genes and pathways involved in IBD can point to new biological mechanisms, potential biomarkers, and future targets for research that may eventually inform diagnosis or treatment.
The review identifies berberine as a potential adjunct therapy for UC because it may target both gut microbes and epithelial inflammasome-mediated cell death, processes important in disease activity and barrier function.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
This study reports that an optimized Cycas revoluta leaf extract reduced colon inflammation and markers of oxidative stress in a rat model of ulcerative colitis, suggesting it could be a source of bioactive compounds...
The article offers an Ayurvedic framework for understanding and managing ulcerative colitis that may interest patients seeking complementary approaches and clinicians exploring integrative care. It emphasizes dietary and...
If true, a commonly available dietary change—drinking alkalinised filtered water—might modestly affect inflammatory markers and specific gut bacteria in people with IBD in remission, which could be of interest to...
This report documents one‑year outcomes after fecal microbiota transplantation in four very ill children across several indications, including a child with Crohn’s disease and severe C.
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
This study identifies KCTD10 as a regulator of intestinal stem cell function and mucosal repair in experimental colitis, which could point to new mechanistic insights about why epithelial healing fails in some cases of...
If endometriosis is linked to other immune, allergic, or chronic pain conditions, people with endometriosis may benefit from broader evaluation and coordinated care beyond gynecology. The review suggests shared...
Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
The study identifies a redox–inflammasome pathway (Nrf2 linked to NLRP3/IL‑1β) relevant to UC and shows that sulforaphane can modulate this axis in intestinal epithelial cells, highlighting a potential therapeutic target...
The gut microbiome and its metabolic pathways are areas of active research in IBD; this study suggests specific genera and predicted functions that could become candidate biomarkers or targets for follow-up studies.
Researchers engineered bispecific antibodies that block two inflammatory pathways (TL1A and IL-12/23p40) simultaneously, a strategy that could overcome limits of single-target therapies in IBD. The work is preclinical...
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...
Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.
Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...
The study identifies how secreted products from Lactobacillus brevis can selectively lower inflammatory gene expression in an intestinal epithelial cell model, pointing to microbiome-derived mechanisms that might become...
The study links microbiome metabolites to reduced epithelial inflammation and improved barrier function via AhR and cholinergic pathways—mechanisms relevant to IBD. This could guide future preclinical and therapeutic...
This work suggests a new experimental target (extracellular vimentin) that reduced inflammation, fibrosis-related markers, and necroptotic cell-death markers in mice and in cultured colon cells — processes that are...
People with ulcerative colitis may eventually have an oral small-molecule option that targets the TNF-α pathway instead of injectable biologics. Early-stage preclinical work suggests a new mechanism (allosteric MKK3...
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and...
New Phase 2b maintenance data suggest a novel anti‑TL1A antibody may provide sustained symptom relief and mucosal improvement for some people with moderate-to-severe UC or CD — outcomes that matter because durable...
Early Phase 1b results suggest PALI-2108 may produce rapid improvements on endoscopy and calprotectin in very small Crohn’s and UC cohorts, which could matter if later trials confirm benefit and safety. The findings are...
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over...
